Consequently, we believe that TGFBR2 represents an ideal target to act against elevated TGFβ concentrations as found in in the context of neurodegenerative disorders, such as ALS, or also in several other diseases like IPF or in immune oncology. Here, TGFBR2 is linked to amyotrophic lateral sclerosis.